Perrigo confirms settlement of generic version of Ofirmev injection Perrigo (PRGO) confirmed that it has agreed to settle its Hatch-Waxman litigation relating to Ofirmev injection brought by Cadence (CADX). Under the terms of the settlement, Perrigo can launch a generic version of Ofirmev injection on December 6, 2020, or earlier under certain circumstances. In addition, Perrigo has secured the right to be the sole authorized generic distributor should Cadence elect to launch an authorized generic product.
News For PRGO;CADX From The Last 14 Days
Check below for free stories on PRGO;CADX the last two weeks.